Skip to content

Clinical Impact of COVID-19 by P.1 SARS-CoV-2 Lineage

Clinical Impact of Coronavirus Disease 19 (COVID-19) Caused by P.1 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Lineage

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04928469
Enrollment
86
Registered
2021-06-16
Start date
2021-06-15
Completion date
2021-07-16
Last updated
2021-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19, COVID-19 Pneumonia, SARS-CoV-2 Infection

Brief summary

Since the first report of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concern (VOC) P.1 in Manaus, Brazil, a rapid spread of this lineage across the country has been observed. Recent studies indicate that this variant is associated with higher transmissibility; it is not known whether it is associated with clinical severity and higher mortality rates. This is a retrospective cohort study carried out at Hospital de Clínicas de Porto Alegre. Adult patients aged 18 years or more and 65 years or less who were admitted to the hospital due to symptomatic COVID-19 from June 2020 to May 2021 and had a reverse transcriptase-polymerase chain reaction (RT-PCR) cycle threshold value for either SARS-CoV-2 N1 or N2 target ≤ 25 were eligible to the study. Samples from 86 patients (43 from June 2020 to November 2020 and 43 from February 2021 to May 2021) were sequenced for further evaluation. These dates were defined since the emergence of P.1 lineage in late January. Clinical data regarding ventilatory support, date of onset of symptoms, laboratory findings and mortality were collected from each patient. This retrospective cohort aims to assess whether the number of days needed for supplementary oxygen either by noninvasive ventilation or high-flow nasal cannula from onset of symptoms differs among patients infected with the P.1 SARS-CoV-2 variant and those infected with other variants.

Interventions

Collection of clinical and laboratory data

Sponsors

Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul, Brazil
CollaboratorOTHER
Hospital de Clinicas de Porto Alegre
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Patients aged 18 to 65 years * Hospital admission due to symptomatic COVID-19 * RT-PCR was collected from June to November 2020 or from February to May 2021

Exclusion criteria

* Patients admitted for reasons other than COVID-19 * Asymptomatic patients with positive routine screening with RT-PCR * Patients transferred from other institutions

Design outcomes

Primary

MeasureTime frameDescription
Time to Advanced Respiratory Support28 days from onset of symptomsNumber of days needed for supplementary oxygen either by noninvasive ventilation or high-flow nasal cannula from onset of symptoms.

Secondary

MeasureTime frameDescription
Arterial oxygen partial pressure (PaO2)/ Fractional inspired oxygen (FiO2) evolution during hospitalization28 day from hospital admissionProportion of patients in each category according to PaO2/FiO2 value: 400-301, 300-201, 200-101, \<=100.
28-day Mortality from onset of symptoms28 days from onset of symptomsDeath for any cause from onset of symptoms
Time to death from onset of symptoms28 days from onset of symptomsNumber of days from the onset of symptoms to death
28-day Mortality from hospital admission28 days from hospital admissionDeath for any cause from hospital admission
Time to death from hospital admission28 days from hospital admissionNumber of days from the hospital admission to death
Days alive and free of supplemental oxygen support.28 day from hospital admissionNumber of days alive and free of supplemental oxygen support
Proportion of patients in each category in the ordinal scale during hospitalization28 days from hospital admissionProportion of patients in each category in the ordinal scale during hospitalization. Ordinal scale levels: 1, patient not hospitalized; 2, hospitalized and not receiving supplemental oxygen; 3, hospitalized and receiving supplemental oxygen; 4, hospitalized and receiving oxygen supplementation administered by a high-flow nasal cannula or noninvasive ventilation; 5, hospitalized and receiving mechanical ventilation or extracorporeal membrane oxygenation; and 6, death.
Need of critical care28 days from hospital admissionProportion of patients admitted to Intensive Care Unit
In-hospital mortality90 days from hospital admissionDeath for any cause during hospitalization
Number of thromboembolic event28 day from hospital admissionNumber of patients with documented deep venous thrombosis or pulmonary embolism
Number of patients requiring renal replacement therapy (RRT)28 day from hospital admissionNumber of patients requiring any form of RRT during hospitalization
Number of patients requiring prone positioning28 day from hospital admissionNumber of patients requiring prone positioning during hospitalization
Time to invasive ventilatory support28 days from onset of symptomsNumber of days from the onset of symptoms to mechanical ventilation or Extracorporeal membrane oxygenation (ECMO)

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026